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Abstract
Background: Research in public health emergencies requires trials to be set up in readiness for activation at short
notice and in anticipation of limited timelines for patient recruitment. We conducted a simulated activation of a
hibernating pandemic influenza clinical trial in order to test trial processes and to determine the value of such
simulation in maintaining trial readiness.
Methods: The simulation involved the Nottingham Clinical Trials Unit, one participating hospital, one manufacturing
unit and the Investigational Medicinal Product (IMP) supplier. During the exercise, from 15 September 2015 to 2
December 2015, clinical staff at the participating site completed the trial training package, a volunteer acting as a
patient was recruited to the study, ‘dummy’ IMP was prescribed and follow-up completed.
Results: Successful activation of the hibernating trial with patient recruitment within 4 weeks of ‘arousal’ as planned
was demonstrated. A need for greater resilience in anticipation of staff absenteeism was identified, particularly in
relation to key trial procedures where the potential for delay is high. A specific issue relating to the IMP Stock Control
System was highlighted as a potential source of error that could compromise the randomisation sequence.
The simulation exercise was well received by site investigators and increased their confidence in being able
to meet the likely demands of the trial when activated. The estimated cost of the exercise was £1995; 90% of
this being staff costs.
Conclusions: Simulated activation is useful as a means to test, and prepare for, the rapid activation of ‘hibernating’
research studies. Whether simulation exercises can also help reduce waste in complex clinical trial research deserves
further exploration.
Trial registration: EudraCT Number 2013-001051-12, ISRCTN72331452. Registered on 6 March 2013.
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Background
There is growing recognition that preparedness for public
health emergencies, such as pandemics, earthquakes or
terrorist attacks, should include the development and set-
up of appropriate research ready for rapid activation [1–4].
As the window of opportunity for research during such
emergencies is often limited, clinical trials set up to
respond to these emergencies are particularly vulnerable to
delays in trial processes.
In multicentre trials, once a site is set up and ready to
start, a common inefficiency is delay in recruiting the
first participant; this, in turn, is associated with poor
overall trial accrual [5]. Careful trial design and set-up
by experienced clinical trial units and investigators can
mitigate against delays arising due to deficiencies in trial
processes. Nevertheless, differing local situations at sites,
or unique trial-specific requirements, may create hurdles
that are not easily anticipated.
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Increasingly, internal pilot studies form an integral
part of large multicentre trials [6]. One of the roles of
pilot studies is the identification and, if possible, correc-
tion of deficiencies or obstacles in trial processes that
may adversely affect recruitment [7]. However, in certain
circumstances, such as in trials to be conducted during
public health emergencies or outbreaks of disease, pilot
studies may not be appropriate, or even possible [1, 8].
The Adjuvant Steroids in Adults with Pandemic influenza
(ASAP) trial has been set up to determine if the early use of
low-dose corticosteroids in adults hospitalised with pan-
demic influenza is beneficial [9]. This trial is part of the UK
NIHR pandemic research portfolio. In order for the results
of the trial to inform and influence clinical management
and health policy within the same pandemic, the trial will
need to complete recruitment within the first few weeks of
the pandemic, with primary outcome results reported as
soon as possible thereafter. Specifically, the ASAP trial will
recruit the first participant within 28 days of activation, and
complete recruitment of 2200 participants at approximately
40 sites in the UK within the first pandemic wave; a dur-
ation of approximately 6 weeks. Minimising obstacles that
might arise during recruitment and require ‘time-costly’
solutions is critical to the success of the trial. There will be
no time to conduct and evaluate a pilot or feasibility study.
Simulation exercises are a recognised means for devel-
oping and improving operational readiness within clinical
practice [10, 11]. We conducted a simulated activation of
the ASAP trial in order to (1) test trial processes and iden-
tify potential problems associated with trial delivery, (2)
enhance training of site investigators and (3) to determine
the value of such simulation in maintaining trial readiness.
Methods
Participating units and staff
The simulation exercise was conducted from 15 September
2015 to 2 December 2015 involving the Nottingham Clin-
ical Trials Unit (NCTU), Derby Teaching Hospitals NHS
Foundation Trust (DTHFT, a participating research site),
Rosemont Pharmaceuticals (supplier of the Investigational
Medicinal Product (IMP) and placebo product) and Not-
tingham Pharmacy Production Unit (one of three manufac-
turing units supporting the trial). Approvals for the
conduct of the ASAP trial at DTHFT were in place from
11 July 2014, after which the trial was placed in ‘hiberna-
tion’. Research personnel involved at DTHFT included the
principal investigator, pharmacist and research nurses. A
junior physician with no prior knowledge of the ASAP
trial agreed to volunteer to participate in the exercise as a
‘patient’; the volunteer gave informed consent towards
their participation. The timing of the simulation exercise
was pre-determined with the cooperation of DTHFT site
investigators and involved testing all relevant trial processes
from the issue of a trial activation alert through to follow-
up of 30-day post-charge secondary outcomes.
Simulated activation process
The trial was activated by the NCTU on 15 September
2015. Figure 1 outlines that range of activities performed
following activation. The volunteer ‘patient’ was asked to
arrive at the Medical Admissions Unit (MAU) at a time of
their choosing 1 month post activation (15 October 2015).
Five members of the acute medical team from the Medical
Admissions Unit at DTHFT were asked to complete the
trial specific on-line training within 4 weeks of activation
(the ASAP trial is set up to be able to recruit no later than
4 weeks from activation). The IMP/placebo product was
delivered to DTHFT via usual distribution channels as
planned in the protocol and local operating procedures
for the ASAP trial; sterile water was used as the trial treat-
ment for the simulated activation.
On the day of recruitment, the local principal investiga-
tor (PI) posed as the volunteer patient’s relative, and re-
corded the time required for trial processes involving the
patient, such as time required to take consent and time
from consent to administration of the IMP; only the PI
from the research team was aware of this recording.
The simulation included ‘live’ prescription for the IMP on
the trust’s electronic prescribing system through to adminis-
tration of the IMP to the volunteer patient but did not
include taking of the IMP by the volunteer patient. The re-
search team at DTHFT entered dummy data into the Case
Report Form. All follow-up procedures were performed ac-
cording to the trial protocol including sending of the postal
questionnaire to the patient 30 days after hospital discharge.
Evaluation
A post-simulation meeting with the DTHFT research
team was convened 3 weeks after ‘recruitment’ to assess
acceptability of the exercise and to share lessons learnt.
Cost expenditure associated with the simulation exer-
cise were calculated using the Nottingham University
Hospitals Research and Innovation Non-commercial
Costing Template (Issued 8 November 2016). The cost-
ing for staff time was based on mid-point of Agenda for
Change NHS banding. All costs were reviewed and ap-
proved by relevant third parties.
Results
Conduct of simulated activation
The trial was activated on 15 September 2015 and IMP
requested from the manufacturer on the same day. The
IMP was delivered to the manufacturing unit 3 days
later (18 September 2015). Following quality control
(QC) checks by the manufacturing unit and subsequent
qualified person (QP) release, IMP was received by the
participating site pharmacy on 13 October 2015 (28 days
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from activation) and placed in a designated secure area
in the MAU according to local trial plans.
Patient recruitment took place on 15 October 2015
(30 days from activation). The total time from research
nurses being alerted of the volunteer patient’s arrival at the
MAU to the IMP being dispensed was 23 min (Table 1).
The patient was discharged from hospital on the day of re-
cruitment and given instructions regarding the continu-
ation of IMP at home; no IMP was actually given to the
patient to take home. A postal questionnaire was sent to
the patient on 16 November 2015 with a response returned
on 2 December 2015 (47 days from hospital ‘discharge’).
Table 1 Improvements following simulated trial activation
Activity Key observations Benefit from simulation
Communication 1. Prompt responses across all parties
2. Incorrect contact details identified
3. Concerns identified regarding resilience of cover in
the event of absenteeism of key personnel associated
with trial processes
1. Improved levels of communication between trial partners
2. Highlighted need for building greater trial resilience at all
levels – key personnel have been identified and asked to organise
appropriate pandemic cross-cover; e.g. 2 ‘deputy’ chief investigators
have been ‘appointed’
Documentation 4. Outdated documents identified
5. Training material well received by clinical and
research staff
3. Improved quality control oversight of trial documentation – all trial
documents are now available from the ASAP trial website to enable
rapid updating and dissemination in a pandemic situation; QC
checks at pre-determined time-points to ensure version control of all
trial documents has been added as a critical trial procedure for the
Coordinating Centre
4. Confirmation of adequacy of trial-specific training material
Pharmacy 6. IMP storage arrangements questioned by QP
7. Stock Control System requirements a risk to
randomisation sequence
8. Time frames for delivery of IMP not stipulated in
‘Agreements’
5. Clarification and confirmation of IMP storage standards – local
pharmacy now required to confirm receipt of distribution carton
pre-packed with 6 IMP packs, without opening the carton and
potentially disrupting the randomisation sequence
6. Stock Control System amended to protect randomisation procedure
7. IMP-related processes revised
Data collection/
database
9. Electronic CRF worked well
10. Database functioned well




12. Good knowledge of the trial
9. Increased confidence of site investigators
10. Verification of required research infrastructure
11. Confirmation of readiness for rapid activation
ASAP The Adjuvant Steroids in Adults with Pandemic influenza trial, CRF Case Report Form, IMP Investigational Medicinal Product, IT information technology, QC
quality control, QP qualified person
Fig. 1 Simulated activation flowchart
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Feedback from site staff
Clinical staff who undertook the trial-specific training
package reported that the format and content of the
training material was clear, precise and relevant to their
role in the trial. Site investigators reported that sufficient
information was provided to them for the conduct of the
trial safely and comprehensively. They felt the simulated
activation had increased their confidence regarding trial
delivery and were supportive of such simulations being
conducted at other sites as well.
Issues identified
Two important issues relating to the distribution and
handling of IMPs were identified. Firstly, a delay was en-
countered in the QC processes following receipt of the
IMP at the manufacturing unit. This was due to the per-
son qualified to conduct the QC – the qualified person
(QP) – being away without suitable cover arrangements in
place. On return, the QP subsequently raised concerns
that the amber-coloured bottle used to store the IMP was
not sufficient to protect the active compound from light
degradation once the bottle was removed from its box and
placed in the transparent trial packaging. Clarification on
this issue had to be obtained from the manufacturer to
the satisfaction of the QP.
Secondly, site pharmacy staff reported that the Stock
Control System required the logging of receipt of each
individual IMP pack; this entailed removing each pack
from the distribution carton which contained six IMP
packs within (see Fig. 2). The distribution carton had
been specially designed for this trial to minimise poten-
tial delays in obtaining trial IMP/placebo within the con-
text of high clinical demands during a pandemic. The
sequence of packs within the distribution carton was an
integral component of the randomisation sequence. The
Stock Control System requirements, therefore, had the
potential to compromise the randomisation sequence.
Other minor improvements relating to communication
channels, trial documentation, trial database set up and
verification of processes were identified (Table 1).
Cost of simulation exercise
The overall estimated cost of the simulated activation
was £1995. Of this, one-off set-up costs incurred by the
Coordinating Centre were £1018 (Table 2); these costs
would have been invariable regardless of the number
of sites activated. Overall, 90% of costs related to staff
costs (£1796).
Discussion
This activation exercise confirmed that the ASAP trial is
in a state of readiness and can be ‘aroused’ from its
current hibernation phase to active recruitment within
4 weeks of activation, as planned [9]. Important practical
issues that had the potential to delay the time from trial
activation to first patient recruitment were identified
and addressed.
A need for greater trial resilience was identified in re-
lation to absenteeism of key personnel important to trial
delivery. During a pandemic, it is estimated that up to
50% of staff may be absent at some point due to illness,
or the need to care for family members who fall ill [12].
Trial Coordinating Centres need to have suitable pan-
demic plans in place, including approved cover arrange-
ments for the chief investigator and other key personnel.
Considerations of resilience extend to the membership
and functioning of the Trial Steering Committee, the
Data Monitoring Committee, and to elements potentially
outside the immediate influence of the trial team, such
as the IMP/placebo product supplier and QPs. Although
the trial team had already developed what were thought
to be appropriate pandemic resilience plans, the simula-
tion exercise revealed further areas for attention.
In the design of the ASAP trial, it was recognised that
conducting a trial during a pandemic would be highly
challenging due to demands on clinical staff and health-
care services. Specifically in relation to randomisation, it
was determined that a web-based or telephone-based
process which required a clinician to contact the trial
team for the randomisation schedule would be too time-
consuming and would deter clinicians recruiting potential
Fig. 2 Investigational Medicinal Product (IMP) distribution carton
Lim et al. Trials  (2017) 18:546 Page 4 of 7
participants. Therefore, it was designed that IMP would
be pre-packed in distribution cartons according to a
computer-generated random sequence. The distributions
cartons would allow for easy storage at hospital admission
points and crucially, would allow clinicians to simply take
the next IMP pack from the distribution carton as part of
the randomisation process. However, the well-established
Stock Control System used by the CTU and which was
designed primarily for a web-based randomisation
process, required the local pharmacy to remove individual
IMP packs from the distribution cartons in order to con-
firm receipt of IMP; with the potential to disturb the ran-
domisation sequence. That this potential problem was not
identified during trial set-up is likely due to the mismatch
between ‘usual’ versus ‘unique’ trial-specific processes.
The costs for the simulation exercise were relatively
modest compared to the overall costs of the trial. We were
unable to reliably estimate likely cost savings arising from
improvements made to trial procedures as a result of the
simulation exercise. Anticipated cost savings are
dependent on the ‘cost’ of slow trial accrual. In the case of
pandemic and public health emergency trials, slow accrual
may result in failure to complete a trial with enormous at-
tendant costs in economic and human terms [13].
The single site design of the simulation exercise is a
study limitation. Potentially, involvement of different
sites might identify different areas for improvement.
However, the majority of issues identified during the
simulation exercise were relevant to the entire trial and
were not site-specific. Hence, repeated simulation exer-
cises involving multiple sites within a single trial may be
associated with decreasing amounts of learning and be
inappropriate. On the other hand, some of the major
benefits of a simulation exercise derive simply from en-
abling local sites to rehearse their trial processes; hence
identifying outdated local processes or new obstacles to
trial delivery which may have arisen during the hiberna-
tion period. These benefits are not manifest as improve-
ments to the trial but as the equally important requirement
to maintain local site trial readiness and interest. Perform-
ing simulation exercises across all sites, whether in clusters
or in totality, will require resources which need to be recog-
nised by all parties, including trial funders. Inevitably, the
simulation exercise included elements that were artificial,
such as the involvement of a junior physician as a ‘simu-
lated patient’. Future improvements to the simulation de-
sign would include employing professional actors as
‘patients’, as is common in simulated medical training exer-
cises. In addition, a large number of ‘patients’ could
be asked to present at the same time, thus simulating
the crowd pressures that would exist during a pan-
demic. These improvements would increase the ver-
acity of the simulation exercise but would also be
associated with higher costs. Ultimately, awareness of
those areas where simulation biases towards improved
performance, or artificiality, enables avoidance of un-
justified conclusions.
Implications
A major challenge in the conduct of studies during pub-
lic health emergencies is the requirement to rapidly re-
cruit sufficient participants before the end of the




A. One-off costs at Coordinating Centre
Internal planning meeting(s) Multiple staff 360 £690.60
Mock activation planning
meetings
Multiple staff 120 £206.76
Development of simulation
documents
Trial manager 120 £39.88
QC of website QA manager 120 £44.02
Review training material Trial manager 60 £19.94




B. Costs of site simulation Coordinating Centre
Planning meeting with site Multiple staff 60 £115.10
Distribution of documents Trial administration 40 £8.79
Activation of IT systems Multiple staff 120 £35.44
Obtain and despatch IMP Multiple staff 50 £14.73
Issue green light Trial manager 10 £3.32
Follow-up questionnaire Trial administration 20 £3.85
Non-staff expenses Cost of IMP/packaging £132.50
IMP delivery £60.00





Planning meetings Multiple staff 60 £107.57
Complete online training Multiple staff 20 £156.16
Complete documents/forms Multiple staff 25 £183.13





Planning meetings Specialist pharmacist 60 £22.89
Receive and dispatch IMP Specialist pharmacist 5 £47.70





IMP Investigational Medicinal Product IT information technology, QA quality
assurance QC quality control, QP qualified person
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emergency; there is no option to extend the recruitment
period because of obstacles encountered during trial de-
livery or slow accrual [14]. During the 2009 influenza
pandemic, a phase III trial of corticosteroids in critically
ill patients was initiated 2 to 3 weeks following the peak
of the pandemic and only managed to recruit 26 partici-
pants before the end of the pandemic; the required sam-
ple size was 438 participants [15]. Similarly, during the
2014 Ebola outbreak in east Africa, at least three clinical
trials were initiated without managing to recruit the re-
quired number of participants before the end of the out-
break [13, 16]. These uncompleted trials leave important
clinical questions unanswered. Simulation exercises allow
potential procedural delays to trial delivery to be identified
and tackled prior to trial activation. This is a major benefit
particularly for public health emergency trials.
Simulation exercises may also be useful for trials with
complex or unusual trial processes. The importance of
trial systems and procedures for efficient trial conduct is
well recognised [17]. In most circumstances, an experi-
enced clinical trial team should be able to pre-emptively
identify all relevant potential hurdles to trial delivery
and address these prior to trial activation. However,
when trial processes deviate from standard patterns, it
can be more difficult to anticipate potential problems.
Conclusions
Simulation exercises to test the adequacy of rapid ‘arousal’
procedures and trial delivery processes should be consid-
ered as a component of the set-up of ‘hibernating’ re-
search studies. Whether simulation exercises can also help
reduce waste in complex clinical trial research deserves
further exploration [18].
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